Erectile dysfunction: The primary care practitioner's view

American Journal of Managed Care

Volumn 5, Issue 3, 1999, Pages 333-341

  Sadovsky, Richard ^a,b   Dunn, Marian ^a   Grobe, B Mayer ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Box 31   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE; YOHIMBINE;

ARTICLE; CLINICAL PRACTICE; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; MALE; MEDICAL ASSESSMENT; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COUNSELING; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SUBLINGUAL DRUG ADMINISTRATION; VISUAL DISORDER;

DISEASE MANAGEMENT; EDUCATION, MEDICAL, CONTINUING; FAMILY PRACTICE; FEMALE; HUMANS; IMPOTENCE; MALE; MEDICAL HISTORY TAKING; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; SEXUAL PARTNERS; UNITED STATES;

EID: 0033059363     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychological correlates: Results of the Massachusetts Male Aging Study. J Urol 1994,151:54-61.
2. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
3. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22:699-709.
4. Wierman ME, Casel CK. Erectile dysfunction: A multifaceted disorder. Hosp Pract October 18, 1998:65-90.
5. Shabsigh R. Is a drug effect part of your patient's complaint of impotence? Contemp Urol 1993;5:51-58.
6. Finger WW, Lung M, Stagle MA. Medications that may contribute to sexual disorders. J Fam Pract 1997;44:33-43.
7. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
8. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983;249:1736-1740.
9. Muller JE, Mittelman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. JAMA 1996;275:1405-1409.
10. Lue TF. Impotence: A patient's goal-directed approach to treatment. World J Urol 1990;8:67-74.
11. Althof SE, Seftel AD. The evaluation and management of erectile dysfunction. Psychiatr Clin North Am 1995;18:171-192.
12. Burnett AL. Erectile dysfunction: A practical approach for primary care. Geriatrics 1998;53:34-48.
13. Goldstein I, Lue TF, Padma-Nathan H, et al, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998,338:1397-1404.
14. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: ACC/AHA Expert Consensus Document. J Am Coll Cardiol 1999;33:273-282.
15. Kunelius P, Hakkinen J, Lukkarinen O. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? Urology 1997;49:441-444.
16. Lawless C, Cree J, Oral medications in the management of erectile dysfunction. J Am Board Fam Pract 1998;11:307-314.
17. Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. October 1996;54:1675-1682.
18. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
19. Linet OI, Prince FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996,334:873-877.